Piflufolastat F 18: Diagnostic First Approval
1Springer Nature, Private Bag 65901, Mairangi Bay, Auckland, 0754, New Zealand. mdt@adis.com.
Molecular Diagnosis & Therapy
|July 22, 2021
Summary
Piflufolastat F 18 (PYLARIFY®) is a new PET imaging agent targeting prostate-specific membrane antigen (PSMA). It aids in detecting prostate cancer metastasis and recurrence, improving diagnostic accuracy.
Area of Science:
- Nuclear medicine
- Radiopharmaceuticals
- Oncology imaging
Background:
- Prostate cancer diagnosis relies on detecting metastasis and recurrence.
- Prostate-specific membrane antigen (PSMA) is a key biomarker in prostate cancer.
- Advanced imaging agents are needed for accurate detection.
Purpose of the Study:
- To summarize the development milestones of Piflufolastat F 18.
- To highlight its approval as a diagnostic agent for prostate cancer.
- To underscore its role in PSMA-targeted PET imaging.
Main Methods:
- Development of an 18F-labelled diagnostic imaging agent.
- Targeting of prostate-specific membrane antigen (PSMA).
- Application in positron emission tomography (PET).
Main Results:
- Piflufolastat F 18 (PYLARIFY®) development by Progenics Pharmaceuticals Inc.
- FDA approval in the USA on May 27, 2021.
- Use in PET imaging for PSMA-positive lesions in prostate cancer.
Conclusions:
- Piflufolastat F 18 represents a significant advancement in prostate cancer diagnostics.
- Its approval facilitates improved detection of metastasis and recurrence.
- PSMA-targeted PET imaging with Piflufolastat F 18 enhances patient management.
![An Automated Radiosynthesis of [68Ga]Ga-FAPI-46 for Routine Clinical Use](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F66708.jpg&w=3840&q=50)
![Automated Preparation of [68Ga]Ga-3BP-3940 on a Synthesis Module for PET Imaging of the Tumor Microenvironment](/_next/image?url=https%3A%2F%2Fcloudfront.jove.com%2FCDNSource%2Fteasers%2F68356.jpg&w=3840&q=50)
Related Concept Videos
01:25Ultrasound II: Endoscopic Ultrasound and FibroScan
253
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
253
01:26FDA Approved Drugs: Changes to Approved Drugs
32
Post-approval, manufacturers may modify an approved new or generic drug product. Such modifications can encompass alterations in the Active Pharmaceutical Ingredient (API), manufacturing process, formulation, batch size, manufacturing site, and container closure system (FDA Guidance for Industry, April 2004). Often, a drug product may undergo multiple changes.These modifications require careful evaluation to determine their potential impact on the drug product's identity, strength, quality,...
32
01:23Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
292
Prostacyclin receptor agonists are a class of therapeutic agents integral to managing pulmonary arterial hypertension (PAH). These drugs operate by mimicking the action of prostaglandin I2, or PGI2, a naturally occurring compound in the body.
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
292